High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry

TY - JOUR

T1 - High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry

AU - Martino, M.

AU - Lanza, F.

AU - Pavesi, L.

AU - Öztürk, M.

AU - Blaise, D.

AU - Leno Núñez, R.

AU - Schouten, H. C.

AU - Bosi, A.

AU - De Giorgi, U.

AU - Generali, D.

AU - Rosti, G.

AU - Necchi, A.

AU - Ravelli, A.

AU - Bengala, C.

AU - Badoglio, Manuela

AU - Pedrazzoli, P.

AU - Bregni, Marco

N1 - Export Date: 14 March 2017 CODEN: BBMTF Correspondence Address: Martino, M.; Hematology and Stem Cell Transplant Unit, Azienda Ospedaliera BMMItaly; email: maxmartino@live.com References: Pedrazzoli, P., Martino, M., Delfanti, S., High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer (2015) J Natl Cancer Inst Monogr, 51, pp. 70-75; Hortobagyi, G.N., What is the role of high-dose chemotherapy in the era of targeted therapies? (2004) J Clin Oncol, 22, pp. 2263-2266; Castagna, L., Martino, M., Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management? (2013) Bone Marrow Transplant, 48, p. 305; Peters, W.P., Ross, M., Vredenburgh, J.J., High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer (1993) J Clin Oncol, 11, pp. 1132-1143; Gianni, A.M., Siena, S., Bregni, M., Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results (1997) J Clin Oncol, 15, pp. 2312-2321; Pedrazzoli, P., Ferrante, P., Kulekci, A., Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999 (2003) Bone Marrow Transplant, 32, pp. 489-494; Weiss, R.B., Rifkin, R.M., Stewart, F.M., High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study (2000) Lancet, 355, pp. 999-1003; Passweg, J.R., Baldomero, H., Bader, P., Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants (2015) Bone Marrow Transplant, 50, pp. 476-482; Nitz, U.A., Mohrmann, S., Fischer, J., Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial (2005) Lancet, 366, pp. 1935-1944; Rodenhuis, S., Bontenbal, M., van Hoesel, Q.G., Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer (2006) Ann Oncol, 17, pp. 588-596; Berry, D.A., Ueno, N.T., Johnson, M.M., High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials (2011) J Clin Oncol, 20, pp. 3214-3223; De Giorgi, U., Amadori, D., Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer (2012) J Clin Oncol, 30, p. 758; Moroni, M., High-dose chemotherapy as adjuvant therapy in breast cancer: could there be a survival benefit? (2012) J Clin Oncol, 30, p. 759; Wang, J., Zhang, Q., Zhou, R., High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis (2012) PLoS One, 7, p. e33388; Peccatori, J., Barkholt, L., Demirer, T., Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation (2005) Cancer, 104, pp. 2099-2103; Ueno, N.T., Rizzo, J.D., Demirer, T., Allogeneic hematopoietic cell transplantation for metastatic breast cancer (2008) Bone Marrow Transplant, 41, pp. 537-545; Harrington, D., Linear rank tests in survival analysis (2005) Encyclopedia of biostatistics, , Wiley Interscience Hoboken, NJ; McCullagh, P., Nelder, J.A., Generalized linear models (Chapman & Hall/CRC monographs on statistics & applied probability) (1989), 2nd ed. Chapman & Hall London, UKPedrazzoli, P., Martinelli, G., Gianni, A.M., Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry (2014) Biol Blood Marrow Transplant, 20, pp. 501-506; Martino, M., Ballestrero, A., Zambelli, A., Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry (2013) Bone Marrow Transplant, 48, pp. 414-418; Tallman, M.S., Gray, R., Robert, N.J., Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer (2003) N Engl J Med, 349, pp. 17-26; Peters, W.P., Rosner, G.L., Vredenburgh, J.J., Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13 (2005) J Clin Oncol, 23, pp. 2191-2200; Kröger, N., Damon, L., Zander, A.R., Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients (2003) Bone Marrow Transplant, 32, pp. 1153-1157; Berry, D.A., Ueno, N.T., Johnson, M.M., High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials (2011) J Clin Oncol, 29, pp. 3224-3231; Basser, R.L., O'Neill, A., Martinelli, G., Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95 (2006) J Clin Oncol, 24, pp. 370-378; Szekely, B., Iwamoto, T., Szasz, A.M., A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories (2013) Breast Cancer Res Treat, 138, pp. 691-698; Markiewicz, A., Wełnicka-Jaśkiewicz, M., Skokowski, J., Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients (2013) PLoS One, 8, p. e72219; Gluz, O., Nitz, U.A., Harbeck, N., Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial (2008) Ann Oncol, 19, pp. 861-870; Marino, P., Roché, H., Moatti, J.P., High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis (2008) Am J Clin Oncol, 31, pp. 117-124; Siena, S., Bregni, M., Di Nicola, M., Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors (1994) Ann Oncol, 5, pp. 935-941; Körbling, M., Fliedner, T.M., The evolution of clinical peripheral blood stem cell transplantation (1996) Bone Marrow Transplant, 17, pp. 675-678; Antman, K.H., Rowlings, P.A., Vaughan, W.P., High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America (1997) J Clin Oncol, 15, pp. 1870-1879

PY - 2016

Y1 - 2016

N2 - The aim of this retrospective study was to assess toxicity and efficacy of adjuvant high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) in 583 high-risk breast cancer (BC) patients (>3 positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years, 57.3% of patients were premenopausal at treatment, 56.5% had endocrine-responsive tumors, 19.5% had a human epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had ≥10 positive lymph nodes at surgery. Seventy-nine percent received a single HDC procedure. Overall transplant-related mortality was 1.9%, at.9% between 2001 and 2005, whereas secondary tumor-related mortality was.9%. With a median follow-up of 120 months, overall survival and disease-free survival rates at 5 and 10 years in the whole population were 75% and 64% and 58% and 44%, respectively. Subgroup analysis demonstrated that rates of overall survival were significantly better in patients with endocrine-responsive tumors,

AB - The aim of this retrospective study was to assess toxicity and efficacy of adjuvant high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) in 583 high-risk breast cancer (BC) patients (>3 positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years, 57.3% of patients were premenopausal at treatment, 56.5% had endocrine-responsive tumors, 19.5% had a human epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had ≥10 positive lymph nodes at surgery. Seventy-nine percent received a single HDC procedure. Overall transplant-related mortality was 1.9%, at.9% between 2001 and 2005, whereas secondary tumor-related mortality was.9%. With a median follow-up of 120 months, overall survival and disease-free survival rates at 5 and 10 years in the whole population were 75% and 64% and 58% and 44%, respectively. Subgroup analysis demonstrated that rates of overall survival were significantly better in patients with endocrine-responsive tumors,

KW - Autologous hematopoietic stem cell transplantation

KW - High-dose chemotherapy

KW - High-risk breast cancer

U2 - 10.1016/j.bbmt.2015.12.011

DO - 10.1016/j.bbmt.2015.12.011

M3 - Article

VL - 22

SP - 475

EP - 481

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -